AI MARKET SCANNING

$RCUS

Arcus Biosciences, Inc.

United StatesUNITED STATES
FREE PREVIEW
📅 Next Earnings: Oct 27, 2026 🌙 Close🌐 Website🏛️ NYSE📁 Healthcare🏭 Biotechnology
AVG HISTORICAL GAP1.80%
MAX GAP RECORD13.18%
PREMIUM
AI ACCURACY RATE
92.4%
Unlock AI Insights 🔓

LAST 10 EARNINGS GAPS (%)

QUANTITATIVE LIVE RADAR BLOTTER

Institutional execution stream for $RCUS

EXECUTIONS0
WIN RATE••.•%
NET ROI+•••.••%
Execution DateStrategy & SetupDirectionExecution RangeHold TimeExit TriggerNet PnL
RADAR SCANNING: WAITING FOR NEXT CATALYST
🔒 Institutional Data Protected

Exact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.

UNLOCK FULL BLOTTER

VOLATILITY & BIAS PROFILE

AVG VOLATILITY4.0%
Bullish Gaps
Bearish Gaps
Neutral

Intelligence Brief

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat,… Read full dossier

CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL

AI INSIGHTS & REPORTS FOR $RCUS

AI REPORT
Aug 17

Weekly Market Recap: A Closer Look at Key Trends

AnalysisThe week has been marked by significant volatility across financial markets, with technology stocks experiencing a notable rout.…
VIEW REPORT_
AI REPORT
Jun 02

Deep Dive into GOTU: Earnings Gap Anticipation and Market Impact

Analysis Text about the earnings gap anticipation for $GOTU, including its impact on stock performance and market trends.…
VIEW REPORT_